fosphenytoin
Enable an agent to recognize fosphenytoin, assess the identity and condition of its material forms, and determine which analytical, handling, or medicinal-use constraints apply.
Bundle → Layer → Finding → Questions Filled
5 bundles · 9 layers · 15 findings · 23 questions
Fosphenytoin identity Resolve the registered substance and the chemical forms represented by incoming records.
Molecular recognition
Establish identity through structure and selective analytical evidence.
Precursor identity test
Require evidence that identifies fosphenytoin separately from phenytoin and other related compounds.
- Which verified structure defines fosphenytoin for this registry entry? definition
- Which analytical result distinguishes the sample from phenytoin and structurally related impurities? measurement
Salt and record boundaries
Attach identifiers and composition to the exact represented form.
Form-specific identifiers
Retain counterion and hydration information when mapping names, identifiers, formulas, and molecular masses.
- Does this record represent the fosphenytoin moiety, a specified sodium salt, a hydrate, or a formulated solution? boundary
- Which authoritative record verifies each identifier for that exact form? provenance
Fosphenytoin material quality Assess intact substance content and the conditions under which a material remains suitable.
Assay and related substances
Measure intact fosphenytoin and distinguish it from phenytoin and other components.
Intact substance content
Record assay basis and separately quantified related substances rather than relying on an unspecified purity percentage.
- What is the fosphenytoin assay on the stated salt, hydration, and moisture basis? measurement
- How much phenytoin and which other related substances are present, with what detection limits? measurement
Phase and stability conditions
Tie physical observations and stability limits to form, solvent, and environment.
Condition-dependent suitability
Require matching conditions before applying solubility, thermal, storage, or degradation evidence to a material.
- Which chemical form, solvent, pH, temperature, and pressure accompany the reported physical property? measurement
- What evidence supports accepting, retesting, or quarantining this material after its recorded storage history? action
Fosphenytoin quantity and conversion Keep substance mass, equivalent quantities, and transformation observations distinct.
Mass and equivalent bases
Make every quantity's chemical and equivalence basis explicit.
PE-aware quantity validation
Require explicit mass or PE units, concentration denominators, and a sourced conversion rule before normalizing quantities.
- Does the value mean actual mass of a specified fosphenytoin form, amount in moles, or phenytoin sodium equivalents? definition
- Which verified conversion rule applies, and has an already PE-labeled value been protected from a second conversion? action
Conversion and analyte resolution
Interpret observations in relation to conversion progress and assay selectivity.
Conversion-sensitive measurement
Some phenytoin immunoassays overestimate concentrations when fosphenytoin remains present; record method and sampling context. [DailyMed prescribing information, section 2.5](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)
- Which analyte and free or total fraction were measured, by which method, and at what sampling time? measurement
- Could assay cross-reactivity or conversion during sample handling explain the reported phenytoin result? boundary
Fosphenytoin use constraints Connect material handling and medicinal-use decisions to applicable evidence.
Grade and handling evidence
Establish what the material's specification and safety documentation actually support.
Form-specific handling basis
Keep chemical hazard classifications, exposure limits, and grade claims scoped to their source, form, and jurisdiction.
- Which current safety data and grade specification apply to this fosphenytoin material? provenance
- What handling or disposal action is supported, and which absent limits remain explicitly unknown? action
Medicinal product interface
Transfer product-dependent and patient-dependent decisions to their owning models.
Clinical constraint handoff
Injection labeling warns of severe hypotension and cardiac arrhythmias associated with rapid intravenous administration. Attach applicable label constraints through the product relationship. [DailyMed boxed warning](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)
- Which authorized product and current jurisdiction-specific label govern the proposed medicinal use? provenance
- Which route, rate, contraindication, and monitoring checks must the clinical model resolve before administration? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of fosphenytoin this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of fosphenytoin this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of fosphenytoin this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of fosphenytoin this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of fosphenytoin this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of fosphenytoin this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of fosphenytoin this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Fosphenytoin is a water-soluble phosphate ester prodrug of phenytoin that is administered parenterally, generally as its sodium salt, and converted enzymatically to phenytoin for antiseizure activity.
In scope
- Fosphenytoin identity and explicit relationships to sodium salts, hydration states, and phenytoin
- Form-specific composition, purity, impurities, and analytical identification
- Physical state, solubility, stability, and storage-condition evidence
- Actual substance quantities and their distinction from phenytoin sodium equivalents
- Bioconversion and analytical interference relevant to recognizing the measured substance
- Substance hazards and links to applicable product labels, safety data, and regulatory records
Out of scope
- Finished injection products, their excipients, packaging, and commercial inventory
- Patient-specific seizure diagnosis, prescribing, dosing, and monitoring plans
- Phenytoin as an independently modeled substance
- Manufacturing processes, equipment, and facility qualification
- Administration devices and clinical procedures
Why it exists Filled
Enable an agent to recognize fosphenytoin, assess the identity and condition of its material forms, and determine which analytical, handling, or medicinal-use constraints apply.
Distinguishing features Filled
- Require a structure-specific identity test separating fosphenytoin from phenytoin; a shared therapeutic relationship does not establish chemical identity.
- Distinguish the fosphenytoin moiety from its sodium salt and any specified hydrate before matching identifiers or comparing molecular masses.
- Fosphenytoin converts to phenytoin after parenteral administration; the precursor and resulting active substance must remain separately identifiable. [DailyMed prescribing information, section 12.3](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)
- A quantity labeled mg PE expresses phenytoin sodium equivalents, not an unqualified mass of fosphenytoin. [DailyMed prescribing information, section 2.1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)
- An injection label identifies a preparation containing a specified fosphenytoin form; it does not establish that every property of that preparation is intrinsic to fosphenytoin.
What robots and AI may and may not do Filled
Must not
- Recommend, calculate or adjust a dose without a clinician's decision.
- Confuse doses expressed as phenytoin equivalents with the salt's own weight.
- Ignore low blood pressure or heart rhythm changes during infusion.
Only with a human decision
- Starting, stopping or changing an infusion, especially in status epilepticus.
May
- Describe fosphenytoin as an injectable prodrug of phenytoin used for seizures.
- Support clinical teams with dose and monitoring records they have authorised.
Moral aspects Filled
- Patients in prolonged seizures cannot speak for themselves; dosing errors cause serious harm.
Who is affected
- Patients with seizures
- Families
- Emergency and intensive care staff
Owners Filled
Steward
The marketing authorisation holder; the treating clinician answers for each use.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.fosphenytoin
- Wikidata: Q5473363 (https://www.wikidata.org/wiki/Q5473363)
Direct properties required Filled
- Chemical form and structural identity: Structure identifier; counterion stoichiometry; hydration or solvation state; unresolved form
- External identity mapping: Verified CAS, PubChem, EC, or other identifier linked to its exact chemical form and source
- Fosphenytoin assay: % mass fraction or molar concentration, with chemical form, water correction, method, and uncertainty
- Phenytoin and other related substances: % or mass concentration for each identified impurity, with detection limits
- Quantity expression basis: mg of specified chemical form; mmol of fosphenytoin; mg PE; corresponding concentration units
- Physical and solution state: Solid or dissolved; solvent; temperature; pH where applicable; observed precipitation
- Conditional physical constants: Solubility in g/L; thermal events in °C; pressure in kPa; exact form and method required
- Conversion relationship: Fosphenytoin precursor to phenytoin, with experimental matrix, conditions, and supporting evidence
- Analytical selectivity: Separately resolves fosphenytoin and phenytoin; cross-reactive; unverified
- Use and hazard evidence: Form-specific safety data, grade specification, jurisdiction, product-label link, and revision date
Recognition required Filled
- A solution for injection in vials; identity and strength are confirmed by label and pharmacy records.
Capabilities and actions required Filled
- Resolve a supplier or laboratory record to fosphenytoin while retaining its exact salt and hydration state.
- Compare a material's identity, assay, and impurity results with a specified intended-use standard.
- Normalize quantities only when the chemical form and actual-mass or PE basis are explicit.
- Flag measurements that cannot distinguish fosphenytoin from phenytoin.
- Evaluate storage excursions against evidence for the same form and preparation.
- Route a proposed medicinal use to the applicable product label and clinical model, or flag missing prerequisites.
Hazards and failure modes required Filled
- Rapid infusion can cause low blood pressure and dangerous heart rhythms.
- Dose unit confusion has led to serious overdoses.
- Itching and tingling during infusion.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns fosphenytoin code N03AB05 within hydantoin derivative antiepileptics.
Context of use required Filled
- Fosphenytoin is encountered in hospital and emergency care as an injectable medicine used in the management of seizures.
- It is also used when temporary parenteral replacement of oral phenytoin is needed.
- Pharmaceutical laboratories examine its identity, purity and formulation quality.
Sources Filled
- Wikidata item Q5473363: fosphenytoin - identity and sense of the item
- Wikipedia: Fosphenytoin - general description of the item
Open questions
- Does vr.tr.fosphenytoin denote the parent chemical entity or an umbrella including sodium and hydrated forms, and does an existing catalogue model already cover it?
- Which CAS, PubChem, EC, formula, and molecular-mass records are verified for each represented chemical form?
- Which authoritative specifications establish assay, water content, phenytoin impurity, other related-substance limits, and grade suitability?
- Which form-specific sources establish solubility, thermal behavior, degradation pathways, and storage limits, including whether melting or boiling values are meaningful before decomposition?
- Which current safety data establish GHS classification, occupational exposure limits if any, and disposal requirements for bulk fosphenytoin forms in the relevant jurisdictions?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q5473363/spec.json